Open AccessThis article is
- freely available
Development of Streptococcus pneumoniae Vaccines Using Live Vectors
Center for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA
School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA
* Author to whom correspondence should be addressed.
Received: 11 October 2013; in revised form: 9 November 2013 / Accepted: 27 December 2013 / Published: 7 January 2014
Abstract: Streptococcus pneumoniae still causes severe morbidity and mortality worldwide, especially in young children and the elderly. Much effort has been dedicated to developing protein-based universal vaccines to conquer the current shortcomings of capsular vaccines and capsular conjugate vaccines, such as serotype replacement, limited coverage and high costs. A recombinant live vector vaccine delivering protective antigens is a promising way to achieve this goal. In this review, we discuss the researches using live recombinant vaccines, mainly live attenuated Salmonella and lactic acid bacteria, to deliver pneumococcal antigens. We also discuss both the limitations and the future of these vaccines.
Keywords: Streptococcus pneumoniae; Salmonella; lactic acid bacteria; BCG; adenoviruses; bacterial vector; viral vector
Citations to this Article
Cite This Article
MDPI and ACS Style
Wang, S.; Curtiss III, R. Development of Streptococcus pneumoniae Vaccines Using Live Vectors. Vaccines 2014, 2, 49-88.
Wang S, Curtiss III R. Development of Streptococcus pneumoniae Vaccines Using Live Vectors. Vaccines. 2014; 2(1):49-88.
Wang, Shifeng; Curtiss III, Roy. 2014. "Development of Streptococcus pneumoniae Vaccines Using Live Vectors." Vaccines 2, no. 1: 49-88.